Jefferies Financial Group Inc. Biomarin Pharmaceutical Inc Call Options Transaction History

Jefferies Financial Group Inc.

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 13, 2024	SELL	$83.81 - $99.0 $2.43 Million - $2.87 Million	-29,000 Reduced 79.45%	7,500 $655,000
Q4 2023 Feb 13, 2024	BUY	$76.22 - $98.51 $1.08 Million - $1.4 Million	14,200 Added 63.68%	36,500 $3.52 Million
Q3 2023 Nov 14, 2023	BUY	$85.07 - $94.48 $1.05 Million - $1.16 Million	12,300 Added 123.0%	22,300 $1.97 Million
Q1 2023 May 15, 2023	SELL	$87.74 - $117.27 $447,474 - $598,077	-5,100 Reduced 33.77%	10,000 $972,000
Q4 2022 Sep 21, 2023	BUY	$80.93 - $108.63 $412,743 - $554,013	5,100 Added 51.0%	15,100 $1.56 Million
Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $1.22 Million - $1.64 Million	15,100 New	15,100 $1.56 Million

635

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Jefferies Financial Group Inc., based on Form 13F filings with the SEC.

Stay updated on Jefferies Financial Group Inc. with notifications on news.